ScinoPharm

TWSE 1789

ScinoPharm Management Presentation

2016 JP Morgan Healthcare Conference

Yung Fa Chen, Ph.D.
President & CEO

Patricia Chou
CFO & VP Corporate Development

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Table of Content

- Overview of ScinoPharm
- ScinoPharm's Strategies and Opportunities
- Operating Results & Outlook

Overview of ScinoPharm

Background

- Established in 1997 in Taiwan and listed on TWSE in 2011, current market cap around US$1.2 billion
- Major shareholders include Uni-President Group, National Development Fund, & Taiwan Sugar
- Facility & organization built in Taiwan by experienced Syntex team, received multiple regulatory inspections from US FDA, Australia, EU, Japan, etc.
- Specializes in high potent/cytotoxic APIs & moves to injectable formulations
- Expanding in China with a marketing base in Shanghai & new GMP plant in Changshu, just inspected by US FDA with zero 483

ScinoPharm

World Class API Facilities

Taiwan

- 6.6 hectares of land, 330K sqft facilities with >200M^3 reactor volume
- 8 of 18 production lines equipped with high potency capabilities for cytotoxic/steroids
- Passed US FDA, EMA, Australian TGA, Japanese PMDA inspections & 300+ cGMP customer audits
- Provides comprehensive contract research & manufacturing services for brand drug companies
- Global Market

China

- 6.6 hectares of land with > 250M^3 reactor volume
- 3 of 7 production lines equipped with high potency capabilities for cytotoxics
- US FDA approved cGMP facility for intermediates & high potency API
- Full scope capabilities in developing and producing APIs from small to large scale for generic & CRAM markets
- Global market including China

Business Overview

- Risk & return balanced model to offer APIs and sterile filling capability for both generic and new drugs
- 80+ generic APIs developed with 27 APIs launched; 55 US DMFs filed (733 DMFs WW), 29 US DMFs in oncology APIs
- 100+ NCE CRAM projects, with 5 launched and 6 in phase III for NDA filing in 2-3 years; The Qualified Asian supplier to provide APIs to global market for multiple commercial NCEs

2015 Sales Distribution

By Business



By Region



By Indication



ScinoPharm

Strong Generics Product Portfolio



ScinoPharm

Diversified CRAM Portfolio

Stage	First Launch Year	Indication	Location
Commercial	2005	Eluting Stent	US
Commercial	2009/2013	Skin Infection/HAP	US/EU
Commercial	2011	Depression	US
Commercial	2012	Obesity	US
Commercial	2013	Seizure	US
Stage	**Est. NDA Filing Year**	**Indication**	**Location**
Phase III	2016	Infections	US / EU / Asia
Phase III	2017	Ovarian Cancer	US / EU
Phase III	2017	Prostate Cancer	US
Phase III	2017	Ovarian Cancer	CN
Phase III	2017	Seizure	US
Phase III	2017	Parkinson's Disease	US

ScinoPharm

ScinoPharm's

Strategies and Opportunities

Long Term Strategies

Transforming to a full-scope pharma company per our core competency of R&D and cGMP manufacturing in high-technical barrier APIs

- **Vertical Integration to Generic Formulations: Developing dossiers per our difficult-to-make APIs to increase value proposition in the supply chain**
- **Innovative Delivery Formulations: Targeted delivery & extended release of proven APIs via 505(b)2 fast track**
- **Brand New Chemical Entities (New Drugs): Collaborating with start-ups & research institutes, focusing on un-met oncology medical needs of high prevalence in Asia**

ScinoPharm

Keys to Generic Formulation Business

- Expanding formulation portfolio
- Building on-site oncology injectable facility and establishing a complete supply chain
- Sustaining B2B model, promoting our formulations via strategic alliance, especially in China and US/EU
- Acquiring critical resources via M&A

Strategic Alliance Highlights

Partner	Product	Indications	Region	Launch Year(E)	Remarks
Genovate	Entecavir	Hepatitis B Viral	Taiwan	2013*	1st co-developed formulation product launch
Sagent	Oncology Injectable	Myeloid Leukemia	US	2016	1st US ANDA filing, triggered US FDA inspection in Changshu site
Foresee	Leuprolide	Prostate cancer	US	2018	505(b)2 NDA CRAM + Equity
Coland	Bortezomib	Multiple Myeloma	China	2019	1st co-developed drug in China to trigger CFDA inspection in Changshu site
	Azacitidine	MDS	China	2021	Co-developed formulation
Lee's Pharma	Fondaparinux	Anti-thrombotic	China	2022	1st self-developed drug in China
	Travoprost Bimatoprost	Glaucoma	China	2022	Co-developed formulations
Nanjing King Friend	Regadenoson	Stress agent for heart scan	China	2021	1st type 3.1 co-developed new drug in China
US partner	Project A	non-small cell lung cancer	US	2018	US NDA 505(b)2 & Paragraph IV filing
US & China partners	Project B	imaging agent	US	2018	Paragraph IV filing

* Already launched

ScinoPharm

ScinoPharm - Oncology API Leader



ScinoPharm

ScinoPharm Pipeline Echoes Therapy Trend



ScinoPharm

Forces Reshaping Chinese Pharma Market

- Policy reform expediting drug approvals, allowing new drug developers to own drug licenses without manufacturing sites
- Significantly lifting the cost structure & entry barrier in Chinese drug market, with a heavy focus on quality and innovation
- Motivating drug makers to improve quality by applying for US ANDAs, which need SPT's world class APIs
- MNCs and emerging virtual-model players creating huge needs in API contract manufacturing in China for global compliance

Advantages in Growing Chinese Market

- **Direct benefit from the new GMP standards and policy reform**
- **Tailor-made product portfolio for Chinese market**
- **Domestic presence plus world-class strengths in:**
  - * High-technical-barrier oncology APIs
  - * Global first tier customer base
  - * Quality and EHS/GMP compliance
- **Bridge between Chinese and global markets**

Portfolio for Chinese Aging Society

- 14 drug licenses applied and 6 collaborated with local marketers for popular age-related diseases in China
- Benazepril as the first granted import drug license

Oncology	Cardiovascular	Urology	Glaucoma	Alzheimer	Others
*Anastrozole	*Benazepril	*Tamsulosin	**Bimatoprost	*Galantamine	*Celecoxib
*Capecitabine	*Bivalirudin		**Travoprost		*Entecavir
*Docetaxel	**Fondaparinux				*Dantrolene
*Gemcitabine	**Regadenoson				
*Irinotecan					
*Paclitaxel					
**Azacitidine					
**Bortezomib					

* Submit drug import license applications or production permits
**Co-developed product targeted for Chinese market

ScinoPharm

Operating Results & Outlook

Historical Performance

Unit: In NT$ million

* For Q1-Q3 only



ScinoPharm

Recent Financial

* In NT$ million

Year	2013	2014	Q1-Q3 or 9/30 2015
Total assets*	11,484M	11,372M	11,995M
Shareholders' equity*	9,643M	9,380M	9,701M
Sales*	5,088M	4,098M	2,925M
Net profit after tax*	1,273M	484M	440M
Earnings per share (NT$)	1.88	0.69	0.60
Cash dividends (NT$/share)	1.2	0.2	-
Stock dividends (NT$/share)	0.4	0.4	-
Pay-out ratio	85%	87%	-

Note : All of the above figures represent consolidated information

ScinoPharm

2016 API Product Launches

Product Name	Region	Indications	Brand Marketer	Regional Sales*	WW Sales*
Azacitidine	USA	Myelodysplastic syndromes (MDS)	Celgene	US$257.2M	US$771.9M
Desmopressin Acetate	USA	Polyuria	Ferring	US$140.1M	US$393.3M
Entecavir	USA, Singapore, Australia	Hepatitis B Virus (HBV)	Bristol-Myers	US$286M (USA only)	US$1591.6M
Flumazenil	Korea	Reversal of the sedative effects of benzodiazepines	Roche	N/A	US$86.2M
Gemcitabine HCl	Middle East	Pancreas, Lung, Ovary, Breast Cancers.	Eli Lilly	N/A	US$583.4M
Tamsulosin	USA	Benign Prostatic Hyperplasia (BPH)	Boehringer Ingelheim	US$411.1M	US$1853.2M

*Source *IMS Data (2014Q3-2015Q2)*

Pipeline Outlook



ScinoPharm

Brand Quality with Asian Advantages

www.scinopharm.com